



METAVAX®

- our proprietary
innovative vaccine platform

METAVAX® our proprietary platform to develop **highly immunogenic chimeric** VLP-based vaccines presenting customer's antigen target.

Our platform is built on the **WHO** recommended production host ***Hansenula polymorpha*** and our **unique duck hepatitis B virus like particle** (dHBs).

www.artes-biotechnology.com

METAVAX®

Competitive **advantages** are:

- ✦ no virus clearance
- ✦ no endotoxins
- ✦ no cross-reactivity

VLP´s for **presentation** of:

- ✦ very large (600 aa) antigens
- ✦ multimeric antigens
- ✦ multiple antigens on 1 VLP
- ✦ conformational epitopes
- ✦ membrane proteins

ARTES offers the proprietary **METAVAX®** platform **for stable, cost efficient** and **fast** vaccine development and manufacturing.

ARTES´ offer includes the delivery of:

- ✦ cell lines
- ✦ production processes
- ✦ analytics
- ✦ preclinical material
- ✦ GMP batches
- ✦ process transfer

Validated for:

Malariaa.o. CSP, AMA1 & MSP2
Flua.o. H5N1 hemagglutinin
Hepatitis CE1/E2
HIVGp140

- ✦ self-adjuvanting vaccines
- ✦ B and T-cell specific immune response

ARTES Biotechnology GmbH

Elisabeth-Selbert-Str. 9, 40764 Langenfeld, Germany, +49 (0) 2173 27587 0

www.artes-biotechnology.com, info@artes-biotechnology.com